• The dose response to a single topical administration of the carbonic anhydrase inhibitor MK-927 was investigated in 24 patients with primary open angle glaucoma or ocular hypertension. Three concentrations of MK-927 (2%, 1%, and 0.5%) and placebo were administered in a two-center, double-masked, randomized, placebo-controlled, four-period crossover study. MK-927 at the 0.5% concentration appeared to be minimally effective in reducing intraocular pressure. A single topical dose of 1% MK-927 resulted in a significantly greater percent reduction in intraocular pressure for up to 6 hours when compared with treatment with placebo. Similarly, a single dose of 2% MK-927 significantly lowered intraocular pressure for 8 hours compared with treatment with placebo. The pressure reduction from baseline measured 23.7% and 11.3% at 8 hours after instillation of a single drop of 2% MK-927. The medication was well tolerated and appeared to lower intraocular pressure in a dose-dependent fashion.
Higginbotham EJ, Kass MA, Lippa EA, Batenhorst RL, Panebianco DL, Wilensky JT. MK-927: A Topical Carbonic Anhydrase Inhibitor: Dose Response and Duration of Action. Arch Ophthalmol. 1990;108(1):65–68. doi:10.1001/archopht.1990.01070030071031
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: